SLAMF1/CD150 in hematologic malignancies: Silent marker or active player?

SLAMF1/CD150 receptor is a founder of signaling lymphocyte activation molecule (SLAM) family of cell-surface receptors. It is widely expressed on cells within hematopoietic system. In hematologic malignancies CD150 cell surface expression is restricted to cutaneous T-cell lymphomas, few types of B-c...

Full description

Saved in:
Bibliographic Details
Published in:Clinical immunology (Orlando, Fla.) Fla.), 2019-07, Vol.204, p.14-22
Main Authors: Gordiienko, Inna, Shlapatska, Larysa, Kovalevska, Larysa, Sidorenko, Svetlana P.
Format: Article
Language:English
Subjects:
Animals
Chronic lymphocytic leukemia
Hematologic malignancies
Hematologic Neoplasms
Hematopoietic cells
Hodgkin's lymphoma
Humans
Signaling Lymphocytic Activation Molecule Family Member 1
SLAMF1/CD150
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SLAMF1/CD150 receptor is a founder of signaling lymphocyte activation molecule (SLAM) family of cell-surface receptors. It is widely expressed on cells within hematopoietic system. In hematologic malignancies CD150 cell surface expression is restricted to cutaneous T-cell lymphomas, few types of B-cell non-Hodgkin's lymphoma, near half of cases of chronic lymphocytic leukemia, Hodgkin's lymphoma, and multiple myeloma. Differential expression among various types of hematological malignancies allows considering CD150 as diagnostical and potential prognostic marker. Moreover, CD150 may be a target for antibody-based or measles virus oncolytic therapy. Due to CD150 signaling properties it is involved in regulation of malignant cell fate decision and tumor microenvironment in Hodgkin's lymphoma and chronic lymphocytic leukemia. This review summarizes evidence for the important role of CD150 in pathogenesis of hematologic malignancies. •CD150 expression on neoplastic cells in hematologic malignancies is distinct from their normal analogues.•CD150 mediates signaling in normal and malignant hematopoietic cells.•CD150 is a potential target for therapeutic intervention in leukemias and lymphomas.•CD150 is an active player in Hodgkin lymphoma and chronic lymphocytic leukemia pathobiology.
ISSN:1521-6616
1521-7035
DOI:10.1016/j.clim.2018.10.015